



Grifols signs an agreement to manage four plasma collection centers in the United States

The Spanish group will have 150,000 more liters of plasma used in fractionation, adding to the 2 million liters of this prime material which are obtained through the 72 plasmapheresis centers owned by the company in the United States

Barcelona, May 4, 2007- Grifols, holding company in the pharmaceutical/hospital sector and fourth in the production of plasma derivatives in the world, has signed an agreement to manage four new plasma collection centers in the United States. Through this agreement, the group will have an additional 150,000 liters of plasma a year for its fractionation plants in Barcelona and Los Angeles. The initial investment was 13 million dollars and once this first stage is completed, another 8 centers will follow suit.

Throughout 2006, the need for additional plasma in Grifols has been met through increases in the capacity of the company's functioning centers, through the incorporation of 22 new centers and through purchase agreements with third parties. The agreement struck with one of these independent companies in the United States will diminish the need to purchase prime material from third parties. The inclusion of these plasma donation centers in the production structure will allow the company to adapt the plasma availability to the fractionation volume, with the aim of increasing plasma derivative production and responding to growing market demands.

Grifols' plasma fractionation capacity is 3.6 million liters of plasma a year and is carried out in the company's two plants located in Parets del Valles (Barcelona) and Los Angeles. This capacity will increase another 700,000 liters a year once the FDA approves the *Minifrac* plant located in the industrial complex in Los Angeles.

About Grifols

Grifols is present in more than 90 countries. Since May 2006, the company has been listed on the Spanish Stock Market and forms part of the IBEX MEDIUM CAP index. Currently it is the first company in Europe in the plasma derivatives sector and the fourth in production in the world. In the following years, the company will strengthen its leadership in the industry as a vertically integrated company thanks to its existing investments which have ensured the company's supply of its primary material, plasma, from 72 plasmapheresis centers in the United States. In terms of fractionation capacity, the manufacturing facilities in Barcelona (Spain) and Los Angeles (USA) will allow the company to respond to growing market demands.